Compare AbbVie Inc (ABBV) vs Prudential PLC (PUK) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

Prudential PLC (PUK) trades at $27.65, up 0.33% today, with a bullish technical outlook and strong fundamentals including a 14.52% net income margin and 21.15% ROE. Recent earnings beat expectations in Q2 and Q4 2025, though Q4 2024 missed. The company shows robust cash flow growth, with operating cash flow reaching $3.61B in 2024, and strategic moves like the Bharti Life Insurance acquisition signal expansion intent. Analyst consensus is mixed but leans positive with 50% buy ratings.

The stock presents a value opportunity with a low P/E of 9.16, but faces risks from regulatory challenges in Japan and market volatility. Upside potential is supported by earnings growth and institutional confidence, though investors should monitor Japan's sales suspension impact and competitive pressures in insurance markets.